CURE welcomes Alliance for Cancer Gene Therapy

Alliance for Cancer Gene Therapy is the only charitable organization in the nation dedicated exclusively to funding and fostering research into cell and gene therapies for cancer. Its mission is to seek out and support revolutionary scientific research into the causes, treatment, and prevention of all types of cancer, using cells and genes as medicine.​ more

By |February 12th, 2017|Uncategorized|0 Comments

Cara recruits for uremic pruritus trial

Cara Therapeutics reports it has initiated patient recruitment for an adaptive Phase 2/3 trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus, an intractable systemic itch condition in patients with chronic kidney disease. There are as yet no approved therapies in the United States. Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. more

By |July 8th, 2016|Uncategorized|0 Comments

CT flexes muscle at San Francisco BIO convention

The world’s bioscience leaders are focused on San Francisco this week as host of the 2016 Bio International, and Connecticut has a significant contingent at the convention making a case for the state becoming a bigger player in the industry. “The whole (international and domestic bioscience) ecosystem is here,” Susan Froshauer, president and chief executive officer of CURE, said Monday during a phone interview with The New Haven Register. A Connecticut reception was attended by more than 100 business leaders, leading researchers, and investors. more CURE video: Connecticut's Bioscience & Technology Community (2016)

By |June 9th, 2016|Uncategorized|0 Comments

29 companies to present at CT BIO Reception

Some of Connecticut's most exciting new companies will be showcasing their technologies and strategies at a poster session June 7 in San Francisco, part of the Connecticut Reception at BIO International. Also on hand for the CT BIO Reception will be guest speakers, including Dr. George Weinstock, who is Professor, Evnin Family Chair and Director of Microbial Genomics, Jackson Laboratory for Genomic Medicine. Scheduled to present are the following:   Allomek Therapeutics   Dura Biotech Mt. Sinai Genetic Testing Laboratory - Connecticut Alva Therapeutics eHealth Sense Nature’s Fingerprint Arvinas HLK Pharmaceuticals NextCure Avitus Orthopaedics IsoPlexis Pharmalex BioPharmaWorks LamdaVision Reinesse Biorasis Lipid [...]

By |June 9th, 2016|Uncategorized|0 Comments

Early-Stage Life Sciences Conference XII

The Early-Stage Life Sciences Conference XII is a showcase for life sciences technologies developed at the universities, research institutions, and hospitals of New England and for recently formed companies. The Forum is an opportunity for these companies and researchers to present to an audience of angel investors, venture capitalists and corporate investors. Companies that have presented at our first eleven Early Stage Life Sciences Conferences have raised over $250 million in new investments. Registration: MATTO members, academics/staff at MATTO member institutions, Presenters and Exhibitors - $100.00 Non-member - $150.00 For more information about the event please Click here or visit [...]

By |February 10th, 2016|Uncategorized|0 Comments

CURE and the Community

Dear CURE Members, This is an exciting time for Connecticut bioscience and CURE is playing an instrumental role. As an important driver of our state’s lifesciences, medical device, and healthcare community, we are actively broadening our impact into areas essential for the continued expansion of Connecticut’s bioscience and life sciences sectors. We work to ensure that large and small companies, entrepreneurs, and mentors connect; that resources, talent, and experts convene; and that we build a robust, vibrant community. I am pleased to share a number of exciting developments and highlight some of our achievements as we move into my third [...]

By |February 1st, 2016|Uncategorized|0 Comments

CURE’s China members receive Shenzhen City award

One year after its start-up in China, HLK (CURE's first overseas member), together with Shenzhen Research Institute of Nanjing, another CURE member, has received a substantial award from the Science and Technology Commission of Shenzhen City. With the proceeds, the two CURE members are building a drug product development center, with emphasis in formulation development technology. more

By |July 20th, 2015|News, Uncategorized|0 Comments

JAX study identifies fusion genes in gastric cancers

Studying the gastric cancers of 15 Southeast Asian patients, researchers at The Jackson Laboratory, the Genome Institute of Singapore and other institutions identified five recurrent fusion genes, one of which appears to lead to cellular changes involved in acute gastritis and cancer. The researchers, led by JAX Professor Yijun Ruan, Ph.D., and Axel M. Hillmer, Ph.D., of GIS, published their findings in the journal Cell Reports ... more Separately, The Jackson Laboratory’s fiscal management practices and commitment to accountability and transparency have earned the nonprofit organization a four-star rating from Charity Navigator, America’s largest independent charity evaluator ... more

By |July 13th, 2015|News, Uncategorized|0 Comments

BMS bets big on gene therapy in deal with uniQure

Bristol-Myers Squibb Company and uniQure N.V. announced today an agreement that provides Bristol-Myers Squibb with exclusive access to uniQure's gene therapy technology platform for multiple targets in cardiovascular diseases. The collaboration includes uniQure's proprietary gene therapy program for congestive heart failure that is intended to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Under the agreement, Bristol-Myers will make over $100 million in up-front payments, licensing fees and equity investments in exchange for the commercial rights to uniQure's lead candidate and [...]

By |April 7th, 2015|News, Uncategorized|0 Comments

What’s next for Pfizer’s vaccines unit?

What's next for Pfizer's vaccines unit? "We are an important growth engine for the company and there are lots of ways to grow. We will continue to grow with our current portfolio--much of which is new anyway--but if we have external opportunities that would be great," Pfizer Vaccines President Susan Silbermann said in a recent interview. article in FierceVaccines Study investigates the efficacy of immunization with Pfizer's Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) to prevent a first episode of vaccine-type pneumococcal community-acquired pneumonia ... more European Commission approves an expanded indication for the use of Prevenar 13 for [...]

By |March 23rd, 2015|News, Uncategorized|0 Comments